Literature DB >> 18955523

OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection.

Thomas J Louie1, Judy Emery, Walter Krulicki, Brendan Byrne, Manuel Mah.   

Abstract

During a 10-day treatment for Clostridium difficile infection, OPT-80 and vancomycin were comparably effective in reducing C. difficile counts. Bacteroides fragilis group counts appeared unaffected with increasing dosages of OPT-80, whereas vancomycin was markedly suppressive. Retention of components of the normal microflora might lower the risk of recurrent disease.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18955523      PMCID： PMC2612159          DOI： 10.1128/AAC.01443-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  In vitro activities of OPT-80 and comparator drugs against intestinal bacteria.

Authors:  Sydney M Finegold; Denise Molitoris; Marja-Liisa Vaisanen; Yuli Song; Chengxu Liu; Mauricio Bolaños
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

2.  Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species.

Authors:  Kim L Credito; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

3.  Colonic microbiota signatures across five northern European countries.

Authors:  Christophe Lay; Lionel Rigottier-Gois; Kim Holmstrøm; Mirjana Rajilic; Elaine E Vaughan; Willem M de Vos; Matthew D Collins; Ralph Thiel; Pawel Namsolleck; Michaël Blaut; Joël Doré
Journal:  Appl Environ Microbiol       Date:  2005-07       Impact factor: 4.792

4.  Effect of vancomycin on intestinal flora of patients who previously received antimicrobial therapy.

Authors:  C Edlund; L Barkholt; B Olsson-Liljequist; C E Nord
Journal:  Clin Infect Dis       Date:  1997-09       Impact factor: 9.079

5.  Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection.

Authors:  T Louie; M Miller; C Donskey; K Mullane; E J C Goldstein
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

6.  Tiacumicins, a novel complex of 18-membered macrolide antibiotics. I. Taxonomy, fermentation and antibacterial activity.

Authors:  R J Theriault; J P Karwowski; M Jackson; R L Girolami; G N Sunga; C M Vojtko; L J Coen
Journal:  J Antibiot (Tokyo)       Date:  1987-05       Impact factor: 2.649

7.  Tiacumicins, a novel complex of 18-membered macrolides. II. Isolation and structure determination.

Authors:  J E Hochlowski; S J Swanson; L M Ranfranz; D N Whittern; A M Buko; J B McAlpine
Journal:  J Antibiot (Tokyo)       Date:  1987-05       Impact factor: 2.649

8.  In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile.

Authors:  R N Swanson; D J Hardy; N L Shipkowitz; C W Hanson; N C Ramer; P B Fernandes; J J Clement
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

9.  Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial.

Authors:  S Johnson; S R Homann; K M Bettin; J N Quick; C R Clabots; L R Peterson; D N Gerding
Journal:  Ann Intern Med       Date:  1992-08-15       Impact factor: 25.391

10.  In vitro activity of OPT-80 against Clostridium difficile.

Authors:  Grit Ackermann; Birgit Löffler; Daniela Adler; Arne C Rodloff
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191
  10 in total
  72 in total

Review 1.  Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance.

Authors:  Dhara Shah; Minh-Duc Dang; Rodrigo Hasbun; Hoonmo L Koo; Zhi-Dong Jiang; Herbert L DuPont; Kevin W Garey
Journal:  Expert Rev Anti Infect Ther       Date:  2010-05       Impact factor: 5.091

Review 2.  Minority report: the intestinal mycobiota in systemic infections.

Authors:  Thierry Rolling; Tobias M Hohl; Bing Zhai
Journal:  Curr Opin Microbiol       Date:  2020-06-27       Impact factor: 7.934

3.  Fidaxomicin: in Clostridium difficile infection.

Authors:  Sean T Duggan
Journal:  Drugs       Date:  2011-12-24       Impact factor: 9.546

4.  In vitro activity of fidaxomicin (OPT-80) tested against contemporary clinical isolates of Staphylococcus spp. and Enterococcus spp.

Authors:  Douglas J Biedenbach; James E Ross; Shannon D Putnam; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2010-03-22       Impact factor: 5.191

Review 5.  Future novel therapeutic agents for Clostridium difficile infection.

Authors:  Hoonmo L Koo; Kevin W Garey; Herbert L Dupont
Journal:  Expert Opin Investig Drugs       Date:  2010-07       Impact factor: 6.206

6.  Sustained clinical response as an endpoint in treatment trials of Clostridium difficile-associated diarrhea.

Authors:  Stuart Johnson; Dale N Gerding; Thomas J Louie; Nancy M Ruiz; Sherwood L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  2012-05-21       Impact factor: 5.191

Review 7.  Chemical probes and drug leads from advances in synthetic planning and methodology.

Authors:  Christopher J Gerry; Stuart L Schreiber
Journal:  Nat Rev Drug Discov       Date:  2018-04-13       Impact factor: 84.694

Review 8.  Treatment of refractory and recurrent Clostridium difficile infection.

Authors:  Christina M Surawicz; Jacob Alexander
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-04-19       Impact factor: 46.802

9.  Comparative microbiological studies of transcription inhibitors fidaxomicin and the rifamycins in Clostridium difficile.

Authors:  Farah Babakhani; Jaime Seddon; Pamela Sears
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

Review 10.  Variations in virulence and molecular biology among emerging strains of Clostridium difficile.

Authors:  Jonathan J Hunt; Jimmy D Ballard
Journal:  Microbiol Mol Biol Rev       Date:  2013-12       Impact factor: 11.056
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.